Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-201 in Dry Eye Disease
NCT05370495Phase 2Completed
- Sponsor
- Seinda Pharmaceutical Corporation
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SY-201 in dry eye disease (DED) (4 arms), sponsored by Seinda Pharmaceutical Corporation. Primary endpoints: Total Corneal Fluorescein Staining at 60 days and Eye Dryness Score at 60 days. Started Jul 2022; status: completed.
02
Drugs
SY-201
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05370495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370495.